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Leukemia stem cells (LSCs) represent a biologically
distinct subpopulation of myeloid leukemias, with
reduced cell cycle activity and increased resistance
to therapeutic challenge. To better characterize key
properties of LSCs, we employed a strategy based
on identification of genes synergistically dysregu-
lated by cooperating oncogenes. We hypothesized
that such genes, termed ‘‘cooperation response
genes’’ (CRGs), would represent regulators of LSC
growth and survival. Using both a primary mouse
model and human leukemia specimens, we show
that CRGs comprise genes previously undescribed
in leukemia pathogenesis in whichmultiple pathways
modulate the biology of LSCs. In addition, our find-
ings demonstrate that the CRG expression profile
can be used as a drug discovery tool for identification
of compounds that selectively target the LSC popu-
lation. We conclude that CRG-based analyses pro-
vide a powerful means to characterize the basic
biology of LSCs as well as to identify improved
methods for therapeutic targeting.
INTRODUCTION
Acute myeloid leukemia (AML) arises in hematopoietic tissues
and manifests in the form of aberrant production and dissemina-
tion of immature white blood cells (Lo¨wenberg et al., 1999).
Although many therapeutic strategies have been tested, AML
is generally very difficult to treat and the majority of patients
ultimately succumb to the disease (Burnett et al., 2011; Estey
and Do¨hner, 2006; Lo¨wenberg et al., 1999). While the reasons
behind the failure of conventional therapy are multifaceted, one
aspect of the problem appears to derive from the cellular and
molecular heterogeneity that is intrinsic to leukemic disease.
Indeed, primary leukemia specimens are clearly complex popu-
lations, which in at least some cases bear remnants of the devel-Cell Sopmental structure found in normal hematopoietic tissues
(Bonnet and Dick, 1997; Hope et al., 2004). Hence, leukemia
stem cells (LSCs) are thought to reside at the apex of a hierar-
chical development process in which the majority of tumor cells
arise from a biologically distinct LSC population. This view of
leukemia pathology suggests that targeting of the LSC compart-
ment will be critical in order to achieve lasting elimination of the
disease. Notably, empirical evidence clearly suggests that LSCs
are relatively quiescent and resistant to conventional chemo-
therapy (Costello et al., 2000; Guzman et al., 2001), thereby
supporting the concept that LSCs are biologically distinct from
bulk tumor cells and indicating that eradication of the malignant
stem cell compartment requires the development of new thera-
peutic strategies.
Due to the clinical importance of targeting LSCs, investigation
of the mechanisms that control their growth and survival has
been an active area of research in recent years. Using mouse
models of AML, several reports have described specific genes
and pathways that are selectively utilized by LSCs. For example,
in leukemias initiated by MLL translocations, dysregulation of
b-catenin (Wang et al., 2010), GSK3-b, and Meis1 (Wong et al.,
2007) has been shown to be important for survival of LSCs. Simi-
larly, Musashi-2 was recently shown to play a key role in the
pathogenesis of LSCs in BCR-ABL-mediated blast crisis (Ito
et al., 2010), and PML-RAR-alpha (Nasr et al., 2008) was demon-
strated to have a central function in a model of acute promyelo-
cytic leukemia. Despite these findings, the overall gamut of
pathways most central to the biology of LSCs, particularly as
they relate to therapeutic targeting, remains largely unknown,
not least because drivers of malignant cell transformation
downstream of oncogenic mutations have been very difficult
to identify.
A general feature of cancers, including leukemia, is the
requirement of multiple cooperating oncogenic mutations for
malignant cell transformation, as for example the manifestation
of acute malignancy as observed in blast crisis CML. Moreover,
recent evidence from a variety of cell types shows that the
process of oncogene cooperation requires synergistic regulation
of downstream targets at multiple levels including gene regula-
tion (Lloyd et al., 1997; Sewing et al., 1997; Xia and Land,
2007). Notably, such targets, i.e., their corresponding genes,tem Cell 11, 359–372, September 7, 2012 ª2012 Elsevier Inc. 359
Cell Stem Cell
Gene Sets Regulating Leukemia Stem Cellshave been demonstrated to be essential for the cancer pheno-
type with high frequency and have been termed ‘‘cooperation
response genes’’ or CRGs (McMurray et al., 2008). The approach
of exploiting the consequences of the genetic interactions
between oncogenes to identify CRGs thus appeared as an
attractive rationale for discovery of critical pathways regulating
LSC biology. In fact, McMurray et al. demonstrated in a colon
cancer cell model, using activated Ras and mutant p53, that
CRGs regulate a wide array of cellular processes, and included
many genes not previously associated with malignancy. Thus,
CRG analysis provides a powerful and relatively unbiasedmeans
by which to identify genes that contribute to oncogenic
transformation.
In the present studies, we employed the CRG strategy in the
context of a mouse model of blast crisis CML, a very aggressive
form of acute leukemia that is usually refractory to conventional
drug therapy. The system employs coexpression of the BCR-
ABL and NUP98-HOXA9 translocation products, which yields
a cooperative oncogenic transformation event and a well-char-
acterized model of human blast crisis CML (Dash et al., 2002;
Neering et al., 2007). Our data show that CRGs are readily
evident in this system and that many of these genes modulate
the in vivo growth of primitive leukemia cells. In addition, we
show that the expression signature of leukemia CRGs can be
utilized as a drug discovery tool to identify pharmacological
agents with selective antileukemia activity. Finally, we extend
our findings to patient-derived specimens and demonstrate
a similar role for CRGs in the biology of primary human leukemic
cell types. Taken together, these findings indicate that analysis
of oncogene cooperation provides important insights into the
biology and potential treatment of leukemic disease.
RESULTS
Identification of Cooperation Response Genes in
Primitive Leukemia Cells
To identify leukemia CRGs,we employed amousemodel of blast
crisis CML that has been shown to mimic human disease (Dash
et al., 2002), and in which we have previously identified and char-
acterized a discrete leukemia stem cell (LSC) population (Neer-
ing et al., 2007). To establish the model, hematopoietic stem
cell (HSC) enriched bone marrow cells were isolated from
C57Bl/6-CD45.1 congenic mice and infected with two indepen-
dent retroviral vectors encoding the human translocation prod-
ucts BCR-ABL and NUP98-HOXA9 (Figure 1A). Each retroviral
vector also expressed a distinct fluorescent protein reporter
(GFP or YFP) to delineate cells transduced with one or both
vectors (Neering et al., 2007). Upon transplantation into C57Bl/
6-CD45.2 recipient animals, transduced cells rapidly engraft
and proliferate with overt disease evident in 10–12 days. The
use of two independent vectors for the initial infections results
in cell populations expressing one or both vectors. These popu-
lations can be easily distinguished and isolated by flow cytomet-
ric sorting (Figure 1A). Cells representing each of the four
possible genotypes (no oncogene, BCR-ABL alone, NUP98-
HOXA9 alone, or both oncogenes) were sorted using a standard
lineage marker panel (lin) to isolate the immature lin compart-
ment, as well as the CD45.1 congenic marker to ensure a pure
population of donor cells. The generation and isolation of each360 Cell Stem Cell 11, 359–372, September 7, 2012 ª2012 Elsevier Ipopulation was repeated in six independent experiments. For
the identification of synergistically regulated genes, genome-
wide transcriptional profiling was performed on sorted cells
using the Affymetrix mouse 430 2.0 microarray platform. Genes
were first filtered based on differential expression between
fully transformed (i.e., BCR-ABL + NUP98-HOXA9) and normal
cells using the Benjamini-Hochberg correction procedure
with a p value cutoff of 0.01. This analysis yielded approximately
3,500 differentially expressed genes (DEGs) representing the
overall transcriptional dysregulation in primitive leukemia com-
pared to normal cells. Next we applied a synergy filter to identify
genes cooperatively regulated by BCR-ABL and NUP98-
HOXA9. This was accomplished by comparing the level of
gene expression in the primitive leukemia cells (BCR-ABL +
NUP98-HOXA9) to that of primitive hematopoietic cells express-
ing each translocation alone (Figure 1B). Synergy was defined as
a greater than additive fold change in gene regulation upon
expression of both oncogenes in the same cell (McMurray
et al., 2008). By applying the synergy criteria to the 3,500
DEGs, a cooperativity response gene set was identified in prim-
itive leukemia. After removal of Riken cDNA and ESTs, the gene
set comprised 72 genes (Table S1 available online), termed the
leukemia cooperation response genes or CRGs (Figure 1C).
Moreover, the expression of each gene in the CRG signature
was uniquely modulated in fully transformed cells (i.e., BCR-
ABL + NUP98-HOXA9) compared to cells bearing the single
translocations (Figure 1C). To corroborate the data obtained
from microarray analyses, we validated the results by quantita-
tive real-time PCR (qRT-PCR), using freshly generated primitive
(lin) leukemic and normal bone marrow cells. Total RNA was
analyzed by qRT-PCR using Taqman Low Density Array
(TLDA), custom designed to detect expression of CRGs. A total
of four independent biological replicates were evaluated. Rela-
tive gene expression was determined in primitive leukemia by
comparison to paired normal controls. The analysis revealed
that over 95% of CRGs identified bymicroarray showed a similar
differential expression when assayed by TLDA (Figure S1).
Given that most of the genes identified were not previously
known to be associated with blast crisis leukemia, we performed
a pathway analysis and gene ontology annotation of the 72
CRGs to characterize the various cellular processes implicated.
Ingenuity Pathway Analysis (IPA) revealed that the CRGs were
present in a diverse set of biological functions such as signal
transduction, metabolism, and cell adhesion (Figure 1D).
The CRG Expression Pattern Is Conserved among
Varying Leukemic Cell Types
A significant challenge in understanding the biology of leukemia
cells is the well-known heterogeneity found in primary malignant
populations (Hope et al., 2004). Indeed, multiple discrete
subpopulations are commonly evident, including the LSC com-
partment. While elucidating factors that control the most primi-
tive cells is a high priority, understanding the biology of all
leukemic cells is also important, since fundamental properties
such as disease dissemination, growth control, drug resistance,
etc. are likely to be shared among many cell types and are highly
relevant to disease pathology. Thus, we sought to determine
whether or not the CRG expression profile derived from lin
leukemia cells was conserved in more primitive as well asnc.
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Figure 1. Determining the Leukemia CRG Profile
(A) Retroviruses encoding BCR-ABL and NUP98-HOXA9were used to infect primitive hematopoietic bonemarrow cells (lineage-, Sca-1+, c-kit+, termed ‘‘LSK’’).
Infected LSK cells were transplanted into sublethally irradiated mice and primitive bone marrow cells from day 10 leukemic animals were purified based on lack
of expression of a standard panel of lineage markers (Ter119, B220, Gr1, and CD3e) and expression of GFP and YFP, which indicates expression of BCR-ABL
or NUP98-HOXA9, respectively. Four separate bonemarrow populations were purified: GFP+/YFP- (BCR-ABL alone), GFP-/YFP+ (NUP98-HOXA9 alone), GFP+/
YFP+ (BCR-ABL +NUP98-HOXA9), andGFP-/YFP- (normal). RNAwas isolated from each cell population and genome-widemicroarray analysis performed using
the Affymetrix mouse 430 2.0 array platform.
(B) Gene expression analysis scheme. CRGs were identified by first determining the differentially expressed genes (DEGs) in primitive acute leukemia samples
(double = GFP+/YFP+) relative to normal cells lacking BCR-ABL and NUP98-HOXA9 expression (WT). Next, expression of DEGs was compared to cells
expressing BCR-ABL or NUP98-HOXA9 alone. Leukemia CRGs (CRGs) were defined as DEGs showing differential gene expression in comparison to both BCR-
ABL and NUP98-HOXA9 expressing cells (see Experimental Procedures for details).
(C) Hierarchical clustering analysis of the genes representing the CRG signature in normal (WT), BCR-ABL, NUP98-HOXA9, and BCR-ABL + NUP98-HOXA9
(double) cells from all six replicates.
(D) Analysis of gene classes represented by CRGs. See also Figure S1 and Table S1.
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distinct subpopulations based on the expression of lineage
markers (lin) as well as the stem cell marker Sca-1. We have
previously shown that Lin/Sca+ leukemia cells are highly en-
riched for LSC content, while lin+ leukemia cells are completely
devoid of LSCs (Neering et al., 2007). Thus, these two popula-
tions were isolated by flow cytometric sorting, along with
the lin/Sca1 compartment, which is enriched for leukemic
progenitor cells. Total RNA was isolated from each sorted spec-Cell Simen and subsequently interrogated using custom-designed
TLDA cards to evaluate the expression of the CRGs. A total of
four independent biological replicates using paired leukemic
and normal cell populations were analyzed. Intriguingly, there
was a strong conservation in relative expression in the majority
of leukemic populations tested (Figure 2). Over 85% of the
CRG signature was maintained across all three cell populations
(mature, progenitor, and LSC-enriched). The conservation of the
signature across varying leukemic cell types suggests thattem Cell 11, 359–372, September 7, 2012 ª2012 Elsevier Inc. 361
Figure 2. Expression of Leukemia CRGs Is Conserved in Mature and Primitive Populations
Leukemic animals were generated as described for Figure 1. Bone marrow was harvested from four independent groups of mice (n = 5 per group) and purified
based on expression of BCR-ABL and NUP98-HOXA9 using GFP and YFP markers, respectively. Normal and leukemic cells were further purified based on
expression of lineage markers and the stem cell antigen Sca-1. As shown in the left panel, three distinct populations were isolated: lineage-positive cells
(population A), lineage-negative progenitors (population B), and LSC-enriched, Lin-/Sca+ (population C). RNA was isolated from each purified population and
analyzed using a custom TLDA designed to interrogate the CRGs. The right panel shows a heatmap of relative expression of the CRGs in mature, progenitor, and
LSC-enriched leukemia cells compared to their respective normal counterparts (green = downregulated, red = upregulated).
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properties that arise from oncogene cooperativity events may
be conserved broadly in leukemic populations. This observation,
along with the differential expression of CRGs in leukemia cells
(versus normal), may have important ramifications for the devel-
opment of improved therapies.
Identification of CRGs that Modulate Leukemia
Growth In Vivo
To test the hypothesis that genes comprising the CRG signature
may have a functional role in the growth of leukemic cells, we
designed an RNAi-based approach as a means to investigate
all upregulated genes in the signature. Of the 72 genes in the
CRG set, 50 were shown to be aberrantly upregulated in
leukemic cells and therefore represent potential targets for
RNAi mediated knockdown (Figure S1). Primitive leukemia cells
were purified from leukemic animals and transduced with
a custom-designed lentiviral RNAi library in which five to ten indi-
vidual shRNAs targeted each upregulated CRG. Twenty-four
hours later, infected leukemia cells were separated into two frac-
tions. The first fraction was transplanted into recipient animals to
determine the outcome of individual shRNA perturbation on
leukemia growth in vivo. Genomic DNAwas immediately isolated
from the remaining cells to determine the time zero shRNA reper-
toire (Figure 3A). After 8 days, bone marrow and spleen cells362 Cell Stem Cell 11, 359–372, September 7, 2012 ª2012 Elsevier Iwere harvested from recipient mice and genomic DNA was
isolated. To determine the relative abundance of each shRNA
before and after in vivo expansion, we subjected the DNA from
all specimens to PCR-based amplification with primers flanking
the shRNA sequence followed by XhoI restriction enzyme diges-
tion to remove the hairpin structure and subsequently analyzed
by Illumina deep sequencing. The entire experiment was
repeated five times to ensure the validity of each gene under
investigation. The fold change for each shRNA in the screen
was determined relative to time zero as well as control shRNAs
(luciferase, LacZ, and RFP) for both bone marrow and spleen
samples (Figure 3B). Depletion was scored as a 5-fold or greater
decrease in shRNA abundance relative to time zero. To minimize
any background from potential off-target effects of the RNAi,
only genes with two or more independent shRNAs achieving
a 5-fold depletion were considered to be true ‘‘drop-outs’’ from
the screen and thereby important for leukemia growth in vivo.
In applying these criteria, we observed that 35 of the 50 targeted
CRGs (i.e., 70%) were depleted from both the bone marrow and
spleen samples (Figure S2). These findings indicate that
a majority of CRGs represent genes of functional relevance to
in vivo growth of primitive leukemia cells.
To corroborate the results from the RNAi screen, we further
characterized six individual CRGs. The genes chosen—CP,
Serinc2, GJB3, PMP22, EphA3, and SerpinB2—representnc.
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with CP representing the least depleted in comparison to control
shRNAs and SerpinB2 representing the most depleted (Fig-
ure 3C). For these experiments, primitive leukemia cells were
isolated by flow cytometry from primary animals and infected
with individual shRNA lentiviruses specific for each gene or a
LacZ shRNA control. The lentiviral vector used for these studies
was designed to also encode the crimson fluorescent protein
(CrFP), which permits identification and quantification of
leukemic cells bearing the shRNA constructs (for example, see
Figure S2). Twenty-four hours later, each sample was evaluated
by flow cytometry to determine the percentage of CrFP+ cells
(time zero) and then transplanted into recipient animals. Bone
marrow was harvested from recipient animals 10 days after
transplant and the percentage of CrFP+ cells present in the
leukemic graft was again determined by flow cytometry. As
shown in Figure 3D, each of the six CRGs tested was targeted
by two independent shRNA lentiviruses and knockdown of these
genes led to reduced leukemia engraftment (Figure 3E). Thus,
each of the genes evaluated contributes to some aspect of the
in vivo behavior of primitive leukemia cells, e.g., engraftment,
growth, survival, etc. To further investigate these genes, we
performed parallel RNAi-mediated knockdown studies of all six
CRGs in normal hematopoietic stem cells and characterized
the in vivo consequences using long-term bone marrow recon-
stitution assays. The results show that in most cases, knock-
down of the CRGs had less effect in long-term engraftment of
normal hematopoietic cells than their leukemia counterparts
(Figures S3 and S4G).
SerpinB2 Is an Important Regulator of LSCDevelopment
and Function
Given that SerpinB2 shRNAs induced the greatest degree of
depletion in the RNAi screen, we chose to more thoroughly
investigate the role of this gene in leukemia. As SerpinB2-defi-
cient animals are available on a C57Bl/6 genetic background,
we obtained SerpinB2/ hematopoietic cells for experimental
analysis. HSC-enriched cells from either SerpinB2/ CD45.2
or wild-type CD45.1 mice were infected with BCR-ABL and
NUP98-HOXA9 as outlined previously (Figure 4A). Equal
numbers of BCR-ABL/NUP98-HOXA9 transduced wild-type or
SerpinB2 KO LSK cells were transplanted into recipient animals
and engraftment of wild-type versus SerpinB2 KO leukemia was
determined at 9 days after transplant (Figure 4A). The analysis re-
vealed a significant reduction of leukemia cells in bonemarrow of
mice transplanted with SerpinB2 KO leukemia cells compared to
wild-type (Figure 4B). Interestingly, engraftment of LSK cells
expressing BCR-ABL alone (a model of chronic myeloid
leukemia) was largely unaffected by loss of SerpinB2, with
similar levels of engraftment observed between wild-type and
SerpinB2 KO leukemia cells (Figure 4C). This observation
supports the role of SerpinB2 specifically in the cooperative
gene interaction that leads to the blast crisis form of the disease.
To rule out possible artifacts due to differential gene transfer effi-
ciency, we performed a competitive transplantation analysis of
SerpinB2 KO versus wild-type leukemia cells, where leukemic
mice were first established with each genotype individually.
Upon development of disease, primary leukemic bone marrow
from each background was harvested, mixed together at equalCell Sratios, and transplanted into secondary CD45.2 recipient mice.
Nine days after transplant leukemic bone marrow was harvested
from recipient animals and analyzed by flow cytometry using
anti-CD45.1 and anti-CD45.2 antibodies. The relative engraft-
ment of wild-type versus SerpinB2/ leukemia was compared
to the input cell ratio (T = 0). The data demonstrate that leukemia
growth is significantly reduced is the absence of SerpinB2
expression (Figure 4D). We next performed limiting dilution
transplantation experiments to determine the LSC frequency in
the absence of SerpinB2. Those studies revealed that the LSC
frequency in SerpinB2 knockout leukemia was reduced when
compared to that of wild-type leukemia (Figures 4E and 4F).
Since loss of SerpinB2 may also generally impair the function
of normal hematopoietic cells, we also performed control exper-
iments in which naive cells (i.e., nonleukemic) from wild-type
versus SerpinB2/ donors were evaluated by competitive repo-
pulation. As shown in Figure S4, no significant changes in hema-
topoietic lineages, engraftment, or LSK cell frequency were
evident for normal SerpinB2/ cells, thereby further supporting
a leukemia-specific function for this gene. As complete loss of
SerpinB2 may represent too severe of a perturbation to evaluate
its role in leukemia, the phenotype was validated using two inde-
pendent shRNAs to suppress but not completely eliminate Ser-
pinB2 expression (Figure S4). The results were virtually identical
to the data obtained using SerpinB2/ cells. Taken together, the
findings above demonstrate that the role of SerpinB2 is specific
to leukemic populations and that the gene plays a previously
unrecognized role in growth of LSCs in vivo.
To further explore the biology underlying SerpinB2-related
phenotype, we performed a series of additional experiments.
First, to examine progenitor activity, we analyzed the in vitro
colony-forming ability of leukemia cells with or without SerpinB2
expression. Primary wild-type or SerpinB2 null leukemia cells
were purified by flow cytometric cell sorting and seeded in meth-
ylcellulose cultures at varying cell doses. After 7 days of culture,
colonies composed of > 50 cells were scored as colony-forming
units (CFUs). As shown in Figure 4G, the colony-forming poten-
tial of SerpinB2/ leukemia cells was significantly reduced
compared to wild-type controls. Next, as previous reports
have suggested an antiapoptotic role of SerpinB2 expression
(Antalis et al., 1998; Dickinson et al., 1995; Park et al., 2005; Ton-
netti et al., 2008), studies were conducted to investigate whether
SerpinB2 confers a survival advantage to leukemia cells. As
shown in Figure 4H, loss of SerpinB2 expression leads to an
increase in Annexin V-positive cells compared to wild-type
controls. Finally, cell cycle analysis showed no significant differ-
ence between wild-type and SerpinB2 KO leukemia cells (Fig-
ure 4I), indicating that the increased frequency of apoptotic cells
was not related to overt changes in proliferative capacity. Taken
together, these data suggest that SerpinB2 mediates an interac-
tion with the in vivo microenvironment that promotes survival of
leukemic stem and progenitor cells.
Pharmacological Antagonism of CRG Expression
Results in Selective Inhibition of Primitive
Leukemia Cells
Given that specific targeting of individual CRGs resulted in inhi-
bition of leukemic cell growth, we reasoned that simultaneous




Figure 3. Identification of CRGs that Regulate In Vivo Growth of Leukemia Cells
(A) Primary leukemia cells were purified from leukemic mice based on lack of lineage marker expression (Ter119, B220, Gr1, and CD3e). Primitive leukemia cells
were then infected with a custom-designed lentiviral RNAi library targeting all upregulated CRGs. Twenty-four hours later, infected cells were harvested and
divided into two fractions. The first sample (time zero) was immediately processed to isolate genomic DNA and the second sample was transplanted into recipient
animals. Five replicates were performed for each RNAi pool. Eight days after transplant, bone marrow and spleen cells were harvested from recipient mice and
genomic DNA was isolated for Illumina Deep Sequencing.
(B) Heatmap showing the fold change across all replicates for each shRNA in the screen relative to time zero for bone marrow and spleen samples
(blue = decreased, red = increased).
(C) Level of depletion determined for Luciferase, LacZ, CP, Serinc2, GJB3, PMP22, EphA3, and SerpinB2 shRNA from the RNAi screen shown in (B). Next, primary
leukemia progenitors were purified and infected with control or CRG shRNA lentiviruses and transplanted into recipient animals. Each CRG was targeted by two
independent shRNA encoding lentiviruses (1, 2).
(D) Gene mRNA knockdown was confirmed by qRT-PCR.
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pharmacological agents we utilized the Broad Institute’s
Connectivity Map (CMAP) database (Lamb, 2007; Lamb et al.,
2006) to identify compounds that reverse the aberrant expres-
sion of CRGs observed in leukemia cells. The CMAP database
comprises a collection of gene expression profiles derived
from small molecule compounds. The database can be queried
with a gene expression signature of interest to identify those
compounds that induce gene expression changes most similar
and/or dissimilar to the query profile. Since we sought to reverse
the gene expression pattern of genes driving pathogenesis (i.e.,
CRGs), we selected agents that induced expression changes
most opposite to CRGs (termed ‘‘negative connectivity’’). The
results of this analysis are shown in Table 1, where the most
negatively connected compound (defined by a maximum score
of1.0) is Tyrophostin AG825, a known ErbB2 inhibitor (Osherov
et al., 1993). Based on the potential ability of this agent to
suppress expression of CRGs, we hypothesized that AG825
would be selectively toxic to primary mouse leukemia cells. To
test this hypothesis, we treated primary normal and leukemia
mouse bone marrow cells in vitro with varying concentrations
of AG825. Twenty-four hours later cell viability of total as well
as more primitive cells (lin, Sca1+) wasmeasured using flow cy-
tometric (Annexin V) analyses. In addition, progenitor function
was assessed by methylcellulose colony-forming assays. The
results show that leukemia cells were eradicated by AG825 in
a dose-dependent fashion (Figure 5A). In contrast, comparative
analyses of leukemia versus normal cells at the bulk, primitive,
and progenitor cell level demonstrate that AG825 is consistently
more toxic to leukemic cell types (Figures 5B–5D). Notably,
normal primitive cells were only modestly affected by AG825,
even at 100 mM, a concentration that was highly cytotoxic to
leukemia cells (Figure 5C). Further, leukemic progenitor fun-
ction was completely ablated at the highest concentrations of
AG825 while normal progenitors were only modestly affected
(Figure 5D).
In addition to AG825, we evaluated the activity of 4-hydroxy-
nonenol (4HNE), a naturally occurring lipid peroxidation product
that was also predicted by CMAP analysis to be a potent modu-
lator of the leukemic CRG signature (Table 1). Notably, in
previous independent studies of human leukemia specimens
we had identified this compound to possess anti-LSC-specific
properties (Hassane et al., 2008). As observed with AG825,
both primary bulk and primitive leukemia cells were highly sensi-
tive to 4HNE at 24 hours (Figure S5). In contrast, normal bulk and
primitive cells were largely unaffected by the drug with toxicity
only observed at the highest concentrations. Similar results
were observed with Staurosporine, another agent predicted
from the CMAP analysis, on murine hematopoietic cells (Fig-
ure S5). Moreover, both AG825 and 4HNE were able to effec-
tively reverse the CRG expression signature in murine bcCML
cells (Figure S6). Taken together, these data indicate that the
CRG signature can be used as a tool to predict pharmacological
agents with selective toxicity to leukemia cells.(E) Ten days after transplant, leukemic bone marrow was analyzed for expression
was compared to time zero (T = 0). Percent engraftment of LacZ control or Serinc
shown (NS = not significant, ***p < 0.001).
See also Figures S2 and S3. All error bars represent standard error of the replica
Cell SExpression and Function of CRGs Is Conserved
in Human Leukemia
Finally, to investigate the relevance of the CRGs in human
leukemia, we analyzed their expression in a panel of eight inde-
pendent BCR-ABL+ blast crisis leukemia patient specimens and
eight normal bone marrow control specimens. In human bone
marrow, stem and progenitor cells are found within the CD34+
population, making this subpopulation roughly equivalent to
murine Sca+/Lin- cells. For relative expression analyses,
CD34+ cells were isolated from each leukemic or normal bone
specimen using flow cytometric cell sorting. Total RNA was
isolated from each specimen and analyzed by qRT-PCR using
a custom TLDA containing all known human orthologs of the
mouse CRGs. Of the 72 CRGs identified in mouse tissue, only
57 could be interrogated on the TLDA due to lack of a clear
human counterpart. Of the 57 genes analyzed, 33were evaluable
based on successful amplification. Of these genes, analysis
revealed 13 whose relative expression in comparing normal
versus leukemic cells was similar in both murine and human
specimens (Figure 6A). Analysis using the Ingenuity Pathway
Analysis (IPA) bioinformatics resource identified cellular devel-
opment, growth, and proliferation pathways among the known
cellular functions (Table S2). The conserved 13 gene signature
was then used to requery the CMAP database for potential inhib-
itory compounds. As observed for murine cells, Tyrophostin
AG825 and 4-HNE were identified as negatively connected
compounds. To test the biological activity of AG825, we treated
leukemic patient samples (blast crisis CML) versus normal bone
marrow specimens for 24 hours with varying concentrations
followed by analysis of cell viability and colony formation ability.
As observed with AG825 treatment of murine leukemia, human
leukemia samples appeared to be more sensitive to the
compound than normal controls (Figure 6B). Further, striking
differential sensitivity to AG825 was observed for progenitor
cells (denoted CFU, Figure 6E) and was also evident for bulk
and phenotypically primitive populations (Figures 6C and 6D).
Biological testing of 4HNE also demonstrated strong leukemia-
specific cytotoxicity, particularly for colony-forming ability (Fig-
ure S7). Taken together, these data suggest the importance of
the CRGs for growth and survival of human leukemia cells.
DISCUSSION
Elucidating the genetic events that mediate leukemia transfor-
mation is an important step toward identifying the overall mech-
anisms regulating leukemia growth and survival. In the present
study, we used a murine model of acute leukemia to identify
genes cooperatively regulated by BCR-ABL and NUP98-
HOXA9 that control in vivo growth of primitive leukemia. We
demonstrated that knockdown of expression in a majority of
upregulated CRGs reduced leukemia growth upon transplanta-
tion into recipient mice. Further, we showed that the CRG
expression signature was conserved in subpopulations enriched
for a broad spectrum of cell types, ranging from relatively matureof crimson marked shRNA expressing cells by flow cytometry and engraftment
2, CP, PMP22, EphA3, or GJB3 shRNA expressing cells relative to time zero is
tes.




Figure 4. SerpinB2 Modulates LSC Activity In Vivo
(A) Primary blast crisis leukemia was generated using HSC-enriched bone marrow cells from either wild-type or SerpinB2 knockout mice by coexpression of
BCR-ABL and NUP98-HOXA9 as previously described.
(B and C) Bonemarrow from primary leukemic animals was analyzed for engraftment of cells expressing both BCR-ABL and NUP98-HOXA9, or BCR-ABL alone,
using flow cytometry (***p < 0.001).
(D) Primary leukemia bone marrow from wild-type and SerpinB2 KO backgrounds were harvested, mixed at equal ratios, and transplanted into secondary
recipient animals. Nine days after transplant, leukemic bonemarrow was analyzed for engraftment of donor leukemia cells using flow cytometry and compared to
time zero (T = 0) (***p < 0.001).
(E) Kaplan-Meier survival analysis of recipient mice transplanted with 1,000 total leukemia cells from either wild-type or SerpinB2 knockout primary
leukemia (*p < 0.01).
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we employed the CRG profile to identify pharmacological
compounds that were selectively cytotoxic to both murine and
human leukemia cells. Taken together, these data identify a set
of genes, previously not described in leukemia, that regulate
the in vivo growth and survival of primitive leukemia cells,
thereby providing a foundation for future research toward eluci-
dating central properties of LSCs.
By integrating analysis of oncogene cooperation with stem cell
biology, we have begun to elucidate gene regulatory architecture
underlying LSC behavior, as well as that of diverse tumor cell
populations in general. The basis for the genetic studies reported
here is the CRG concept that was first demonstrated in a model
in which mutant Ras and p53 cooperatively mediate oncogenic
transformation of colonic crypt cells (McMurray et al., 2008).
Notably, these studies essentially defined ‘‘oncogene coopera-
tivity’’ in molecular terms, demonstrating that the complex
process of malignant cell transformation largely depends on
the expression of downstream genes responding synergistically
to regulation by multiple oncogenic mutations. In the present
study, we demonstrate the relevance of the previously described
molecular architecture of oncogene cooperation in leukemia,
where CRGs were readily identified. This observation is a
conceptual departure from the interpretation that leukemia
arises via a ‘‘two-hit’’ model in which one oncogene provides a
mitogenic signal (e.g., BCR/ABL) and a second oncogene serves
to increase self-renewal (e.g., Nup98/HoxA9), thus assuming
independence or additive behavior of the oncogene functions
involved. In contrast, our data support the view that leukemo-
genesis is driven by highly cooperative processes yielding acute
malignancy. We thus conclude that oncogene cooperativity, as
defined by synergistic modulation of downstream targets, is
indeed an inherent feature of leukemia biology.
The use of a primary leukemia model to study the role of CRGs
has provided several intriguing observations. First, we were able
to evaluate the expression and activity of CRGs in multiple
stages of leukemia development. As reported previously, the
BCR/ABL + NUP98/HOXA9 model shows considerable cellular
heterogeneity, with a large proportion of cells displaying at least
partial differentiation (as indicated by expression of various
markers associated with mature lineages), but with several other
distinct subpopulations more closely associated with stem or
progenitor populations (as indicated by expression of markers
such as c-kit, sca-1, CD150, Flt3, etc.) (Neering et al., 2007).
Notably, the expression of CRGs was well conserved across
a broad spectrum of stages ranging from mature to primitive.
Thus, we propose that by designing therapeutic strategies
based on pathways identified by CRG analysis, it should be
possible to create regimens that are potentially effective against
both bulk tumor as well as more primitive stem and progenitor
populations. From a conceptual standpoint, simultaneous and
comprehensive targeting of heterogeneous cell populations(F) Limiting dilution results for LSC frequency between wild-type and SerpinB2 k
(G) Colony-forming ability of primary wild-type or SeprinB2 KO bcCML (GFP+/Y
(H) Percentage of apoptotic wild-type or SeprinB2 KO leukemia cells analyzed b
(I) Cell cycle analysis performed on primary wild-type or SerpinB2 KO leukemia,
See also Figure S4. All error bars represent standard error of the replicates.
Cell S(including the LSC compartment) represents an attractive
approach to improving leukemia therapy. A second notable
aspect of the present CRG studies is the use of a targeted shRNA
library for in vivo identification of genes that are directly relevant
to leukemia pathogenesis. Using a genetic drop-out screen
strategy, in a single experiment we were able to simultaneously
evaluate the role of aberrantly upregulated CRGs. These studies
suggest that CRGs are relevant to in vivo growth of leukemic
cells at high frequency, an observation further confirmed by
detailed analyses of six individual genes.
In terms of specific genes, these studies identified several new
regulators of leukemia pathogenesis. Notably, genes in the
leukemia CRG profile were generated from freshly isolated
primary cells, thereby capturing expression data indicative of
native in vivo signals. Subsequent analysis using the lentiviral
RNAi library demonstrated almost no functional role for most of
the CRGs for cells cultured in vitro over the span of eight days,
which was in striking contrast to the in vivo studies (data not
shown). This observation suggests that the CRGs represent
genes important for the development and survival of leukemia
cells in their in vivo microenvironment. Interestingly, the genes
chosen for independent validation—SerpinB2, GJB3, PMP22,
Serinc2, CP, and EphA3—are all implicated in extracellular or
cellular communication activity. For example, GJB3 is a gap
junction protein whose cellular role is thought to be involved in
cell-to-cell communication. Studies suggest that GJB3 binds
to another gap junction protein, GJA1, to form a heterodimeric
junction complex in ES cells (Wo¨rsdo¨rfer et al., 2008). Moreover,
GJA1 (Connexin 43) has been reported to be important for
support of hematopoietic stem and progenitor cell development
and survival (Cancelas et al., 2000). Our data demonstrate that
knockdown ofGJB3 in primitive leukemia reduces growth in vivo,
suggesting that GJB3 is an important regulatory signal for path-
ogenesis. Similarly, both CP and SerpinB2 have extracellular
functions. CP acts to maintain proper cellular iron homeostasis
by influencing iron transport. Previous studies have shown that
in certain cancer types iron import is elevated (Brookes et al.,
2006), possibly in response to a greater need for metabolic
processes. Extracellular SerpinB2 is thought to inhibit the uroki-
nase plasminogen activator (UPA) and thereby prevent plasmin-
ogen activation; however, the actual role SerpinB2 in the
plasminogen response is not well understood. Studies in endo-
metrial cancer have reported that SerpinB2 expression is corre-
lated with increased invasiveness and decreased long-term
patient survival (Gleeson et al., 1992; Nordengren et al., 2002).
Our results demonstrating that SerpinB2 expression is important
for leukemia growth in vivo suggest that its activity could protect
leukemia cells from apoptotic cell death in vivo. Our data further
suggests that SerpinB2 is an important regulator of LSC devel-
opment, in that loss of expression reduces the LSC frequency
in the developing leukemia. EphA3 is a receptor tyrosine kinase
that activates a signal transduction cascade when secretednockout leukemias determined by L-CALC (Stem Cell Technologies), n = 10.
FP+) and CML(GFP+) cells (*p < 0.01).
y Annexin V staining (***p < 0.001).
n = 10.
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rosiglitazone HL60 hgu133a 0.849921146
yohimbine MCF7 u133AofAAv2 0.833242887
deferoxamine PC3 hgu133a 0.810877648
staurosporine MCF7 hgu133a 0.784517747
LY-294002 MCF7 u133AofAAv2 0.779534308
thioridazine MCF7 hgu133a 0.739939595




cobalt chloride MCF7 hgu133a 0.713366654
NU-1025 MCF7 hgu133a 0.698630633
minocycline MCF7 u133AofAAv2 0.687270265
LY-294002 MCF7 u133AofAAv2 0.670194206
clozapine MCF7 hgu133a 0.663687044
5224221 MCF7 u133AofAAv2 0.656678467
trifluoperazine MCF7 hgu133a 0.643054546
carbamazepine MCF7 u133AofAAv2 0.632176605
5248896 MCF7 u133AofAAv2 0.631981557
Ara-C primaryAML1 hgu133plus2 0.621453076
TTNPB MCF7 hgu133a 0.605754727
5252917 MCF7 u133AofAAv2 0.600199581
fulvestrant MCF7 u133AofAAv2 0.596498871
5182598 MCF7 u133AofAAv2 0.569870646
estradiol MCF7 u133AofAAv2 0.563035483
doxycycline MCF7 u133AofAAv2 0.535758294
trichostatin A MCF7 u133AofAAv2 0.531625057
phenanthridinone MCF7 u133AofAAv2 0.525721398
W-13 MCF7 hgu133a 0.524775982
ikarugamycin MCF7 u133AofAAv2 0.521146751
raloxifene MCF7 hgu133a 0.517786179
tretinoin HL60 hgu133a 0.516975031
prazosin MCF7 u133AofAAv2 0.506939292
phenyl biguanide MCF7 hgu133a 0.49527295
valproic acid MCF7 u133AofAAv2 0.493871119
chlorpromazine MCF7 hgu133a 0.487556832
colchicine MCF7 hgu133a 0.447879508
monensin MCF7 u133AofAAv2 0.436030095
genistein PC3 hgu133a 0.430373293
TTNPB PC3 hgu133a 0.430033398
tioguanine MCF7 hgu133a 0.421921152
trichostatin A MCF7 u133AofAAv2 0.418453342
staurosporine MCF7 hgu133a 0.409294748
LY-294002 SKMEL5 hgu133a 0.40882847
phenformin MCF7 hgu133a 0.396945788










valproic acid MCF7 u133AofAAv2 0.360150576
fulvestrant MCF7 hgu133a 0.315383178
The 72 gene LCRG signature was used to query the Broad Institute’s
Connectivity Map (CMAP). The top 49 negatively correlated compounds
are shown.
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EphA3may represent a sensor of secreted molecules promoting
leukemia growth in the marrow microenvironment. Collectively,
identification of these genes as regulators of leukemia growth
in vivo provides further insight on the critical role of leukemia
cell extrinsic signals and niche interactions.
In principle, the genetic data derived using the CRG method-
ology should ultimately guide the development of pharmacolog-
ical agents that selectively target leukemia cells. However,
discerning how to link genomic and chemical interactions can
be challenging and inmany cases there are nowell-defined strat-
egies to achieve this goal. Hence, in the present studies we
turned to the CMAP resource as a means to perform in silico
chemogenomic analyses of gene expression profiles derived
from cooperation response studies. Our previous studies have
demonstrated that both positive and negative connectivity with
the CMAP can be used toward identification of agents that target
leukemia stem cells (Hassane et al., 2008; Hassane et al., 2010).
We adapted this approach to the expression profiles derived
from CRG studies and successfully identified two agents, Tyro-
phostin AG825 and 4-hydroxynonenal (4HNE), that demon-
strated clear activity toward primitive leukemia cells, with
substantially less toxicity to normal cell types. Although AG825
was developed as an ErbB-2 inhibitor, we speculate that
modulation of this pathway is not a central to leukemia-specific
cell death, since subsequent experiments with the clinical
ErbB-2 inhibitor Lapatinib demonstrated no difference in activity
between normal and leukemia cells (data not shown). Thus, it will
be of interest to further characterize the mechanism by which
AG825 targets leukemia cells. Importantly, these data highlight
the utility of using the CRG approach to identify compounds
that would most likely never have been selected based solely
on their documented mechanism of action.
While biological analyses of disease processes in mouse
models can be very powerful, it is important to validate such
approaches in human tissue as well. Hence, we evaluated
patient-derived leukemia specimens and successfully identified
human orthologs of CRGs in primary samples derived from CML
blast crisis patients. Unlike the murine studies, each human
specimen analyzed (eight total) was derived from an indepen-
dent patient with a unique genetic background. Furthermore,
while the specimens all possess the canonical BCR-ABL muta-
tion, additional mutations resulting in blast crisis certainly differ
in each patient. Thus, it is very unlikely that the murine CRG
profile would be completely conserved in each human spec-
imen. Rather, as shown, a subset of CRGs demonstrated similarnc.
AB C D
Figure 5. Tyrophostin AG825 Is Selectively Cytotoxic to Primitive Murine Leukemia Cells
(A) Leukemic bone marrow cells were treated overnight with increasing concentrations of Tyrophostin AG825 (AG825). The following day, cells were harvested
and analyzed by flow cytometry to determine relative toxicity to leukemic (GFP+/YFP+) versus normal cells (GFP-/YFP-).
(B and C) Normal or leukemia cells treated with AG825 overnight were harvested and labeled with annexin V and DAPI to analyze cell death using flow cytometry.
Viability of bulk and primitive cells (Lin-) exposed to AG825 is shown.
(D) Normal or leukemic cells were treated with AG825 overnight followed by methylcellulose culture to measure colony formation ability, CFU (***p < 0.001). See
also Figure S5 and S6. All error bars represent standard error of the replicates.
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the core subset of CRGs was still able to identify AG825 and
4HNE via CMAP analysis, an observation that strongly supports
the functional relevance of genes conserved between murine
and human tissues.
In conclusion, the findings presented in this report provide the
first genetic analysis of cooperatively regulated genes in primi-
tive leukemia cells. We report a subset of genes that influence
multiple aspects of leukemia biology and the interaction ofmalig-
nant cells with the surroundingmicroenvironment. The relevance
of the CRG signature is supported by both genetic analysis of
specific genes and the fact that compounds with predicted
inhibitory activity toward the CRG signature led to leukemia-
specific cytotoxicity in both mouse and human cells. These
data provide intriguing insights into the synergistic nature of
the LSC transformation process, and thus may yield promising
strategies for effective rational drug design for the treatment of
leukemia.
EXPERIMENTAL PROCEDURES
Generation of bcCML Mouse Model
The blast crisis CMLmousemodel was created as described previously (Neer-
ing et al., 2007). Briefly, 6- to 8-week-old naive B6.SJL-Ptprca Pepcb/BoyJ
mice were purchased from Jackson Laboratories (Bar Harbor, ME). Donor
mice were sacrificed and bone marrow was harvested from the tibias and
femurs. Mature lineage-positive cells were depleted from the bone marrow
cell suspension using the BD IMAG immunoaffinity kit (San Jose, CA) per
manufacturer instructions. Purified populations of LSK cells were isolatedCell Susing fluorescently conjugated antibodies specific for Sca1 and c-Kit and
the BD FACS ARIA II cell sorter (San Jose, CA). Donor LSK cells were plated
in one well of a 24-well cell culture plate coated with retronectin (Takara,
Japan) at 1 3 106 cells per ml and cultured overnight in IMDM (Invitrogen)
media supplemented with 10% FBS (Invitrogen), rmIL3 (10 ng/ml), rmIL6
(10 ng/ml), rmFlt3 (25ng/ml), and rmSCF (50 ng/ml) (Peprotech, Rocky Hill,
NJ). The following day, LSK cells were infected with viral supernatant (resus-
pended in 50% viral supernatant and 50% 23 cytokine supplemented media)
twice, once in the morning and again in the evening. The infections were
repeated on day 3. On day 4, the cells were harvested and resuspended in
cold PBS + 2% FBS and subsequently injected through the retro-orbital sinus
into recipient sublethally irradiated (600 rads) 6- to 8-week-old C57Bl6J mice
(Jackson Laboratories, Bar Harbor, ME). The LSK dose was 20,000–40,000
cells per mouse for all experiments and the transduction efficiencies were typi-
cally 10%–15% for BCR-ABL + NUP98-HOXA9 infected cells and between
20% and 30% for BCR-ABL- and NUP98-HOXA9-infected cells. All animal
experiments were approved by University Committee on Animal Resources
(UCAR) at the University of Rochester.
Microarray Gene Expression Analysis
Total RNA for sorted wild-type cells or cells harboring BCR-ABL, NUP98-
HOXA9, or BCR-ABL + NUP98-HOXA9 was harvested on the basis on fluores-
cent protein expression using BD FACS ARIA II flow cytometry sorter (San
Jose, CA). RNA was labeled and amplified according to the NuGen procedure
and hybridized to Affymetrix Mouse 430 2.0 gene expression microarrays
(Affymetrix, Santa Clara, CA). Data analysis was performed using R and Bio-
Conductor (Gentleman et al., 2004). Microarray data were normalized using
the dChip method of Li and Wong (Li and Wong, 2001) with mismatch probe
correction. The data were log2-transformed and differentially expressed genes
were identified using the limma (Smyth, 2004) with p value correction per-
formed according to the Benjamini-Hochberg procedure (Benjamini and
Hochberg, 1995). Genes responding synergistically to the presence of bothtem Cell 11, 359–372, September 7, 2012 ª2012 Elsevier Inc. 369
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Figure 6. Expression and Function of Leukemia CRGs Is Conserved in Human Blast Crisis Leukemia Specimens
(A) Total RNA was isolated from CD34-enriched human or primitive murine leukemia cells and analyzed by qRT-PCR using custom TLDA designed to interrogate
the CRGs. The relative expression in leukemia compared to normal counterparts was determined (n = 8 human, n = 6 mouse). The 13 genes conserved between
the two species and their relative expression are shown.
(B) Normal or leukemic human specimens were treated overnight with increasing concentrations of Tyrophostin AG825 (AG825). Twenty-four hours later the cells
were harvested and labeled with annexin V and DAPI for analysis of cell death using flow cytometry.
(C and D) Viability of bulk and primitive (lin-) human cells treated with AG825 for 24 hr. (E) Normal or leukemic human cells were treated with AG825 overnight
followed by methylcellulose culture to measure colony formation ability, CFU (*p < 0.01), **p < 0.01, ***p < 0.001).
See also Figure S7 and Table S2. All error bars represent standard error of the replicates.
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cooperation response gene (CRG) identification procedure (McMurray et al.,
2008). Briefly, if a corresponds to the mean expression for gene g in BCR-
ABL+ cells, b corresponds to the mean expression value of g in NUP98-
HOXA9+ cells, and d corresponds to the mean expression value of g in










The significance of the CRG scores was determined using a jackknife subsam-
pling procedure to generate estimated CRG score p values for each gene.
Significant genes were selected for follow up analysis. The expression of
CRGs in different cell subsets was visualized using average linkage hierar-
chical clustering using Pearson correlation as a distance measure. Data are
deposited in GEO with accession number GSE37907.
Primary RNAi Library Screen
Primary mice were generated as described previously. Spleens from ten
primary mice were harvested and pooled into a single-cell suspension
following alkaline RBC lysis. Leukemic spleenocytes were depleted of mature
lineage-positive cells using the BD IMAG immunioaffinity kit and cells express-
ing only BCR-ABL (GFP) and NUP98-HOXA9 (YFP) were purified using the BD
FACS ARIA II cell sorter. Immature leukemic (lineage negative) cells were
plated in serum-free conditions at 23 106 cells per ml and cultured overnight.
The following day 3 3 106 cells were infected with lentiviral RNAi viral pools
(Broad Institute, Boston, MA) for 6 hours in 800 ml total volume and 4 mg/ml
polybrene (Millipore, Billerica, MA). The MOI for each shRNA virus was held
constant at 0.1–0.2. Each pooled infection was performed five independent
times to yield five replicates for each pool. After infection, 1 ml of fresh media
was added to the infected cells and cultured overnight. The next day (24 hr)
each sample was split: one-third was resuspended in 1 ml cold PBS and
stored at 20C for time zero; one-third was plated in 1 mg/ml of puromycin
(Invitrogen) to select for transduced cells; and the remaining one-third
(1 3 106 cells) was injected into one recipient mouse per replicate. Eight
days later, the puromycin-selected cells were harvested, resuspended in
1 ml cold PBS, and stored at 20C. Bone marrow and spleens were har-
vested from all recipient mice and processed into single-cell suspensions
with subsequent resuspension in 1 ml cold PBS and stored at 20C.
Genomic DNA was isolated from all samples using QIAamp Blood Kits
(QIAGEN, Valencia, CA). DNA concentration and purity (A260/A280, A260/
A230) was determined using the Nanodrop 1000 (Thermo Scientific).
Sequencing analysis of shRNA representation is described in detail in the
Supplemental Experimental Procedures.
Drug Treatments
Human or mouse cells were cultured in serum-free media (IMDM [GIBCO] sup-
plemented with 20%BIT [BSA, insulin, transferrin; StemCell Technologies, no.
09500], LDL [EMD], B-ME [GIBCO], Pen/strep [GIBCO], and L-glutamine
[GIBCO]) for 24 hr in the presence of Tyrphostin AG825 (Sigma, St. Louis,
MO) at 25, 50, 75, and 100 mM or 4-hydroxy-2-nonenal (EMD, Gibbstown,
NJ) at 5, 10, 20, and 30 mM. The following day, cells were harvested and
analyzed for cell death with Annexin V/DAPI staining using the LSRII flow cy-
tometer (BD, San Jose, CA) or plated in methylcellulose media (Stem Cell
Technologies, Vancouver, Canada) for CFU assay.
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Microarray data have been deposited in Gene Expression Omnibus (GEO) with
accession number GSE37907.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two tables, seven figures, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.stem.2012.05.024.Cell SACKNOWLEDGMENTS
The authors gratefully acknowledge Randall Rossi, Monica Guzman, andMark
Noble for many helpful discussions and critical evaluation of the work and
manuscript. We also thank Timothy Bushnell and the URMC Flow Cytometry
Core for help with cell sorting experiments and Chris Proschel for supplying
the SerpinB2/ animals. The research was supported by NIHRO1-
CA122206, NIHRO1-CA138249, New York State Stem Cell Foundation grant
C024964, Department of Defense grant W81XWH-07-1-0601, and University
of Rochester Hematology/Oncology Training Grant T32-HL007152.
Received: October 24, 2011
Revised: April 23, 2012
Accepted: May 18, 2012
Published online: August 2, 2012REFERENCES
Antalis, T.M., La Linn, M., Donnan, K., Mateo, L., Gardner, J., Dickinson, J.L.,
Buttigieg, K., and Suhrbier, A. (1998). The serine proteinase inhibitor (serpin)
plasminogen activation inhibitor type 2 protects against viral cytopathic effects
by constitutive interferon alpha/beta priming. J. Exp. Med. 187, 1799–1811.
Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate:
a practical and powerful approach to multiple testing. J. R. Stat. Soc., B 57,
289–300.
Bonnet, D., and Dick, J.E. (1997). Human acute myeloid leukemia is organized
as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3,
730–737.
Brookes, M.J., Hughes, S., Turner, F.E., Reynolds, G., Sharma, N., Ismail, T.,
Berx, G., McKie, A.T., Hotchin, N., Anderson, G.J., et al. (2006). Modulation
of iron transport proteins in human colorectal carcinogenesis. Gut 55,
1449–1460.
Burnett, A., Wetzler, M., and Lo¨wenberg, B. (2011). Therapeutic advances in
acute myeloid leukemia. J. Clin. Oncol. 29, 487–494.
Cancelas, J.A., Koevoet, W.L., de Koning, A.E., Mayen, A.E., Rombouts, E.J.,
and Ploemacher, R.E. (2000). Connexin-43 gap junctions are involved in multi-
connexin-expressing stromal support of hemopoietic progenitors and stem
cells. Blood 96, 498–505.
Costello, R.T., Mallet, F., Gaugler, B., Sainty, D., Arnoulet, C., Gastaut, J.A.,
and Olive, D. (2000). Human acute myeloid leukemia CD34+/CD38- progenitor
cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis,
reduced immunogenicity, and impaired dendritic cell transformation capac-
ities. Cancer Res. 60, 4403–4411.
Dash, A.B., Williams, I.R., Kutok, J.L., Tomasson, M.H., Anastasiadou, E.,
Lindahl, K., Li, S., Van Etten, R.A., Borrow, J., Housman, D., et al. (2002). A
murine model of CML blast crisis induced by cooperation between BCR/
ABL and NUP98/HOXA9. Proc. Natl. Acad. Sci. USA 99, 7622–7627.
Dickinson, J.L., Bates, E.J., Ferrante, A., and Antalis, T.M. (1995). Plasminogen
activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced
apoptosis. Evidence for an alternate biological function. J. Biol. Chem. 270,
27894–27904.
Estey, E., and Do¨hner, H. (2006). Acute myeloid leukaemia. Lancet 368,
1894–1907.
Gentleman, R.C., Carey, V.J., Bates, D.M., Bolstad, B., Dettling, M., Dudoit, S.,
Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004). Bioconductor: open soft-
ware development for computational biology and bioinformatics. Genome
Biol. 5, R80.
Gleeson, N., Gonsalves, R., and Bonnar, J. (1992). The plasminogen activator
urokinase and its inhibitor PAI-2 in endometrial cancer. Gynecol. Oncol. 47,
58–61.
Guzman, M.L., Neering, S.J., Upchurch, D., Grimes, B., Howard, D.S., Rizzieri,
D.A., Luger, S.M., and Jordan, C.T. (2001). Nuclear factor-kappaB is constitu-
tively activated in primitive human acute myelogenous leukemia cells. Blood
98, 2301–2307.tem Cell 11, 359–372, September 7, 2012 ª2012 Elsevier Inc. 371
Cell Stem Cell
Gene Sets Regulating Leukemia Stem CellsHassane, D.C., Guzman, M.L., Corbett, C., Li, X., Abboud, R., Young, F.,
Liesveld, J.L., Carroll, M., and Jordan, C.T. (2008). Discovery of agents that
eradicate leukemia stem cells using an in silico screen of public gene expres-
sion data. Blood 111, 5654–5662.
Hassane, D.C., Sen, S., Minhajuddin, M., Rossi, R.M., Corbett, C.A., Balys, M.,
Wei, L., Crooks, P.A., Guzman, M.L., and Jordan, C.T. (2010). Chemical
genomic screening reveals synergism between parthenolide and inhibitors
of the PI-3 kinase and mTOR pathways. Blood 116, 5983–5990.
Hope, K.J., Jin, L., and Dick, J.E. (2004). Acute myeloid leukemia originates
from a hierarchy of leukemic stem cell classes that differ in self-renewal
capacity. Nat. Immunol. 5, 738–743.
Ito, T., Kwon, H.Y., Zimdahl, B., Congdon, K.L., Blum, J., Lento, W.E., Zhao,
C., Lagoo, A., Gerrard, G., Foroni, L., et al. (2010). Regulation of myeloid
leukaemia by the cell-fate determinant Musashi. Nature 466, 765–768.
Lamb, J. (2007). The Connectivity Map: a new tool for biomedical research.
Nat. Rev. Cancer 7, 54–60.
Lamb, J., Crawford, E.D., Peck, D., Modell, J.W., Blat, I.C., Wrobel, M.J.,
Lerner, J., Brunet, J.P., Subramanian, A., Ross, K.N., et al. (2006). The
Connectivity Map: using gene-expression signatures to connect small mole-
cules, genes, and disease. Science 313, 1929–1935.
Li, C., andWong,W.H. (2001).Model-based analysis of oligonucleotide arrays:
expression index computation and outlier detection. Proc. Natl. Acad. Sci.
USA 98, 31–36.
Lloyd, A.C., Obermu¨ller, F., Staddon, S., Barth, C.F., McMahon, M., and Land,
H. (1997). Cooperating oncogenes converge to regulate cyclin/cdk
complexes. Genes Dev. 11, 663–677.
Lo¨wenberg, B., Downing, J.R., and Burnett, A. (1999). Acutemyeloid leukemia.
N. Engl. J. Med. 341, 1051–1062.
McMurray, H.R., Sampson, E.R., Compitello, G., Kinsey, C., Newman, L.,
Smith, B., Chen, S.R., Klebanov, L., Salzman, P., Yakovlev, A., and Land, H.
(2008). Synergistic response to oncogenic mutations defines gene class
critical to cancer phenotype. Nature 453, 1112–1116.
Nasr, R., Guillemin, M.C., Ferhi, O., Soilihi, H., Peres, L., Berthier, C.,
Rousselot, P., Robledo-Sarmiento, M., Lallemand-Breitenbach, V., Gourmel,
B., et al. (2008). Eradication of acute promyelocytic leukemia-initiating cells
through PML-RARA degradation. Nat. Med. 14, 1333–1342.372 Cell Stem Cell 11, 359–372, September 7, 2012 ª2012 Elsevier INeering, S.J., Bushnell, T., Sozer, S., Ashton, J., Rossi, R.M., Wang, P.Y., Bell,
D.R., Heinrich, D., Bottaro, A., and Jordan, C.T. (2007). Leukemia stem cells in
a genetically definedmurinemodel of blast-crisis CML. Blood 110, 2578–2585.
Nordengren, J., Fredstorp Lidebring, M., Bendahl, P.O., Bru¨nner, N., Ferno¨,
M., Ho¨gberg, T., Stephens, R.W., Wille´n, R., and Cassle´n, B. (2002). High
tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an
independent marker for shorter progression-free survival in patients with early
stage endometrial cancer. Int. J. Cancer 97, 379–385.
Osherov, N., Gazit, A., Gilon, C., and Levitzki, A. (1993). Selective inhibition of
the epidermal growth factor and HER2/neu receptors by tyrphostins. J. Biol.
Chem. 268, 11134–11142.
Park, J.M., Greten, F.R., Wong, A., Westrick, R.J., Arthur, J.S., Otsu, K.,
Hoffmann, A., Montminy, M., and Karin, M. (2005). Signaling pathways and
genes that inhibit pathogen-induced macrophage apoptosis—CREB and
NF-kappaB as key regulators. Immunity 23, 319–329.
Sewing, A., Wiseman, B., Lloyd, A.C., and Land, H. (1997). High-intensity
Raf signal causes cell cycle arrest mediated by p21Cip1. Mol. Cell. Biol. 17,
5588–5597.
Smyth, G.K. (2004). Linear models and empirical bayes methods for assessing
differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol.
3, Article3.
Tonnetti, L., Netzel-Arnett, S., Darnell, G.A., Hayes, T., Buzza, M.S., Anglin,
I.E., Suhrbier, A., and Antalis, T.M. (2008). SerpinB2 protection of retinoblas-
toma protein from calpain enhances tumor cell survival. Cancer Res. 68,
5648–5657.
Wang, Y., Krivtsov, A.V., Sinha, A.U., North, T.E., Goessling, W., Feng, Z., Zon,
L.I., and Armstrong, S.A. (2010). The Wnt/beta-catenin pathway is required for
the development of leukemia stem cells in AML. Science 327, 1650–1653.
Wong, P., Iwasaki, M., Somervaille, T.C., So, C.W., and Cleary, M.L. (2007).
Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell
potential. Genes Dev. 21, 2762–2774.
Wo¨rsdo¨rfer, P., Maxeiner, S., Markopoulos, C., Kirfel, G., Wulf, V., Auth, T.,
Urschel, S., von Maltzahn, J., and Willecke, K. (2008). Connexin expression
and functional analysis of gap junctional communication in mouse embryonic
stem cells. Stem Cells 26, 431–439.
Xia, M., and Land, H. (2007). Tumor suppressor p53 restricts Ras stimulation of
RhoA and cancer cell motility. Nat. Struct. Mol. Biol. 14, 215–223.nc.
